Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis

Oncologist

Volumn 22, Issue 4, 2017, Pages 470-479

  Nishijima, Tomohiro F ^a   Shachar, Shlomit S ^b   Nyrop, Kirsten A ^a   Muss, Hyman B ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Division of Oncology   (Israel)

Author keywords

Chemotherapy; Meta analysis; PD 1 PD L1 inhibitor; Systematic review; Toxicity

Indexed keywords

ATEZOLIZUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ANOREXIA; CHEMOTHERAPY; COLITIS; CONSTIPATION; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INSOMNIA; MALIGNANT NEOPLASM; MELANOMA; META ANALYSIS; NAUSEA; NON SMALL CELL LUNG CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; ADVERSE DRUG REACTION; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; DISEASE FREE SURVIVAL; GENETICS; PATHOLOGY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85017474192     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0419     Document Type: Review

References (34)

1. Ribas A. Releasing the brakes on cancer immunotherapy. N Engl J Med 2015; 373: 1490-1492.
2. Postow MA, Callahan MK,Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974-1982.
3. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
4. Weber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16: 375-384.
5. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell nonsmall- cell lung cancer. N Engl J Med 2015; 373: 123-135.
6. Ribas A, Puzanov I, Dummer R et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): A randomised, controlled, phase 2 trial. Lancet Oncol 2015; 16: 908-918.
7. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous nonsmall- cell lung cancer. N Engl J Med 2015; 373: 1627-1639.
8. Herbst RS, Baas P, Kim DW et al. Pembrolizumab versus docetaxel for previously treated, PD-L1- positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016; 387: 1540-1550.
9. Fehrenbacher L, Spira A, Ballinger M et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016; 387: 1837-1846.
10. Nivolumab (Opdivo) prescribing information. Available at http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed September 30, 2016.
11. Pembrolizumab (Keytruda) prescribing information. Available at http://www.merck.com/ product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf. Accessed September 30, 2016.
12. Atezolizumab (Tecentriq) prescribing information. Available at http://www.gene.com/download/ pdf/tecentriq_prescribing.pdf. Accessed September 30, 2016.
13. ClinicalTrials.gov. Available at https://clinicaltrials. gov. Accessed September 30, 2016.
14. Michot JM, Bigenwald C, Champiat S et al. Immune-related adverse events with immune checkpoint blockade: A comprehensive review. Eur J Cancer 2016; 54: 139-148.
15. Bacon CG, Giovannucci E, Testa M et al. The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients. Cancer 2002; 94: 862-871.
16. Butler L, Bacon M, Carey M et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004; 22: 2461-2468.
17. Moher D, Liberati A, Tetzlaff J et al. Preferred reporting items for systematic reviews and metaanalyses: The PRISMA statement. J Clin Epidemiol 2009; 62: 1006-1012.
18. Reeve BB, Mitchell SA, Dueck AC et al. Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials. J Natl Cancer Inst 2014; 106: dju129.
19. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996; 17: 1-12.
20. Higgins JP, Thompson SG, Deeks JJ et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
22. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
23. Egger M, Davey Smith G, Schneider M et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
24. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: Power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53: 1119-1129.
25. Nishino M, Sholl LM, Hodi FS et al. Anti-PD-1- related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373: 288-290.
26. Naidoo J, Page DB, Li BT et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015; 26: 2375-2391.
27. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at http://evs.nci.nih.gov/ftp1/CTCAE/ About.html. Accessed October 20, 2016.
28. Xiao C, Polomano R, Bruner DW. Comparison between patient-reported and clinician-observed symptoms in oncology. Cancer Nurs 2013; 36: E1-E16.
29. Basch E, Jia X, Heller G et al. Adverse symptom event reporting by patients vs clinicians: Relationships with clinical outcomes. J Natl Cancer Inst 2009; 101: 1624-1632.
30. Long GV, Atkinson V, Ascierto PA et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: Results from the phase III CheckMate 066 study. Ann Oncol 2016; 27: 1940-1946.
31. Nishijima TF, Muss HB, Shachar SS et al. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev 2016; 45: 30-37.
32. Singh H, Kim G, Maher VE et al. FDA subset analysis of the safety of nivolumab in elderly patients with advanced cancers. J Clin Oncol 2016; 34:(suppl; abstr 10010).
33. +/- patient population with metastatic nonsmall cell lung cancer. Abstract ORAL02.02. Abstract presented at: 16th World Conference on Lung Cancer; September 6-9, 2015; Denver, Colorado.
34. Grainne M. O’Kane, Catherine Labbé, Mark K. Doherty et al. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer. The Oncologist 2017; 22: 70-80.